Anti-Vimentin antibody [V9] - Cytoskeleton Marker
| Name | Anti-Vimentin antibody [V9] - Cytoskeleton Marker |
|---|---|
| Supplier | Abcam |
| Catalog | ab8069 |
| Prices | $400.00 |
| Sizes | 100 µg |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Clone | V9 |
| Applications | ICC/IF ICC/IF FC IHC-F IHC-P IHC-F WB |
| Species Reactivities | Rat, Horse, Chicken, Bovine, Cat, Dog, Human, Pig |
| Antigen | Porcine Lens |
| Description | Mouse Monoclonal |
| Gene | VIM |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
ab8069 staining Vimentin in HeLa cells. The cells were fixed with 4% formaldehyde (10min), permeabilized with 0.1% Triton X-100 for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated overnight at +4°C with ab8069 at 1/100 dilution (shown in green) and ab195889, Mouse monoclonal to alpha Tubulin (Alexa Fluor® 594), at 2µg/ml (shown in red). Nuclear DNA was labelled with DAPI (shown in blue).Image was taken with a confocal microscope (Leica-Microsystems, TCS SP8).
IHC image of ab8069 staining Vimentin in normal human kidney formalin-fixed paraffin-embedded tissue sections*, performed on a Leica Bond. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab8069, 1/500 dilution, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. No primary antibody was used in the negative control (shown on the inset).For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
ab8069 staining Vimentin in pig cardiac fibroblasts by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with acetone and permeabilized with 0.1% Triton X-100. Samples were incubated with primary antibody (1/100 in PBS pH 7.4) for 30 minutes. A FITC-conjugated goat anti-mouse IgG polyclonal (1/20) was used as the secondary antibody.See Abreview
![All lanes : Anti-Vimentin antibody [V9] - Cytoskeleton Marker (ab8069) at 1 µg/mlLane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell LysateLane 2 : MOLT4 (Human acute lymphoblastic leukemia cell line) Whole Cell Lysate Lysates/proteins at 10 µg per lane.SecondaryGoat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilutiondeveloped using the ECL techniquePerformed under reducing conditions.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_5/19955_Vimentin-Primary-antibodies-ab8069-4.jpg)
All lanes : Anti-Vimentin antibody [V9] - Cytoskeleton Marker (ab8069) at 1 µg/mlLane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell LysateLane 2 : MOLT4 (Human acute lymphoblastic leukemia cell line) Whole Cell Lysate Lysates/proteins at 10 µg per lane.SecondaryGoat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilutiondeveloped using the ECL techniquePerformed under reducing conditions.
IHC image of Vimentin staining in human Hodgkin's Lymphoma formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab8069, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX
![Overlay histogram showing HeLa cells stained with ab8069 (red line). The cells were fixed with methanol (5 min) and then permeabilized with 0.1% PBS-Triton for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab8069, 1/20 dilution) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HeLa cells fixed with 4% paraformaldehyde (10 min)/permeabilized in 0.1% PBS-Triton used under the same conditions.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_5/19957_Vimentin-Primary-antibodies-ab8069-6.jpg)
Overlay histogram showing HeLa cells stained with ab8069 (red line). The cells were fixed with methanol (5 min) and then permeabilized with 0.1% PBS-Triton for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab8069, 1/20 dilution) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HeLa cells fixed with 4% paraformaldehyde (10 min)/permeabilized in 0.1% PBS-Triton used under the same conditions.
ab8069 staining Vimentin in human epithelial ovarian serous adenocarcinoma cell line SKOV-3 by Immunocytochemistry/ Immunofluorescence.Samples were fixed with 4% PFA in PBS pH 7.4 and then permeabilised using 0.2% saponin for 30 minutes. A blocking step was performed using 1% BSA/PBS for 1 hour. Samples were then incubated with ab8069 at a 1/200 dilution in 1% BSA/PBS for 1 hour. The secondary antibody was a goat anti-mouse Alexa 488 (green) diluted 1/1000, 1% BSA/PBS for 1 hour. Samples were then incubated with phalloidin (red for actin staining) in 1% BSA/PBS for 45 minutes and counterstained with DAPI (blue for nuclei staining) in PBS for 45 minutes.
ICC/IF image of ab8069 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab8069, 1µg/ml) overnight at +4°C. The secondary antibody (green) was ab96879, DyLight® 488 goat anti-mouse IgG (H+L) used at a 1/250 dilution for 1h.Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
ab8069 staining Vimentin in Human oral cavity tissue sections by Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections). Tissue was fixed with paraformaldehyde and blocked with ab64226 Protein Block for 5 minutes at 25°C; antigen retrieval was by heat mediation in pH 6 buffer . Samples were incubated with primary antibody (1/1000 in 10% NGS) for 16 hours at 4°C. An undiluted biotinylated goat anti-rabbit polyclonal IgG was used as the secondary antibody.See Abreview
ab8069 staining Vimentin in rat glial cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with formaldehyde and blocked with 1% BSA for 10 minutes at 25°C. Samples were incubated with primary antibody (1/200) for 10 hours at 4°C. An Alexa Fluor® 555-conjugated anti-mouse IgG polyclonal (1/300) was used as the secondary antibody.See Abreview
Product References
MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by - MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by
Xue X, Zhang Y, Zhi Q, Tu M, Xu Y, Sun J, Wei J, Lu Z, Miao Y, Gao W. Cell Commun Signal. 2014 Oct 1;12(1):62.
Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition - Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition
Soon PS, Kim E, Pon CK, Gill AJ, Moore K, Spillane AJ, Benn DE, Baxter RC. Endocr Relat Cancer. 2013 Jan 7;20(1):1-12.
Impact of laminitis on the canonical Wnt signaling pathway in basal epithelial - Impact of laminitis on the canonical Wnt signaling pathway in basal epithelial
Wang L, Pawlak EA, Johnson PJ, Belknap JK, Eades S, Stack S, Cousin H, Black SJ. PLoS One. 2013;8(2):e56025.
Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical - Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical
Wu Y, Fu Y, Zheng L, Lin G, Ma J, Lou J, Zhu H, He Q, Yang B. Cancer Lett. 2014 Jan 1;342(1):82-91.
Establishment and characterization of primary glioblastoma cell lines from fresh - Establishment and characterization of primary glioblastoma cell lines from fresh
Mullins CS, Schneider B, Stockhammer F, Krohn M, Classen CF, Linnebacher M. PLoS One. 2013 Aug 7;8(8):e71070.
Expression of CD82 in human trophoblast and its role in trophoblast invasion. - Expression of CD82 in human trophoblast and its role in trophoblast invasion.
Zhang Q, Tan D, Luo W, Lu J, Tan Y. PLoS One. 2012;7(6):e38487.
Macrophage secretory products induce an inflammatory phenotype in hepatocytes. - Macrophage secretory products induce an inflammatory phenotype in hepatocytes.
Melino M, Gadd VL, Walker GV, Skoien R, Barrie HD, Jothimani D, Horsfall L, Jones A, Sweet MJ, Thomas GP, Clouston AD, Jonsson JR, Powell EE. World J Gastroenterol. 2012 Apr 21;18(15):1732-44.
Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer - Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer
Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Buchler MW, Zoller M, Salnikov AV, Herr I. Cancer Res. 2010 Jun 15;70(12):5004-13.
Dietary polyphenol quercetin targets pancreatic cancer stem cells. - Dietary polyphenol quercetin targets pancreatic cancer stem cells.
Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, Giese N, Moldenhauer G, Wirth T, Buchler MW, Salnikov AV, Herr I. Int J Oncol. 2010 Sep;37(3):551-61.
Can lineage-specific markers be identified to characterize mesenchyme-derived - Can lineage-specific markers be identified to characterize mesenchyme-derived
Singh SR, Billington CK, Sayers I, Hall IP. Am J Physiol Lung Cell Mol Physiol. 2010 Aug;299(2):L169-83. doi: